Personalized Molecular Insights for Integrative Oncology
At Internal Healing and Wellness MD (IHAWMD), patients may explore advanced molecular cancer testing through RGCC International, a laboratory known for circulating tumor cell analysis and functional oncology testing. These tests are designed to provide additional biological insight that may support personalized cancer care discussions alongside standard oncology treatment plans.
RGCC testing analyzes circulating tumor cells (CTCs), molecular markers, and treatment response indicators using blood or tissue samples. This approach is often described as a liquid biopsy, as it evaluates tumor-related activity from a blood sample and may help patients and clinicians better understand tumor biology within an integrative oncology framework.
Disclaimer: RGCC testing is intended to provide educational and biological insight. It does not replace oncology diagnostics, imaging, or treatment guidance from a licensed oncologist.
What Is RGCC Testing?
Research Genetic Cancer Center (RGCC) is a specialized laboratory originally established in Greece that focuses on molecular cancer testing and circulating tumor cell analysis.
The laboratory’s testing platform combines several types of analysis, including:
- Circulating tumor cell detection
- Molecular profiling of cancer-related markers
- Functional drug sensitivity screening
- Immune-related biomarker evaluation
These advanced laboratory techniques aim to provide a more detailed picture of tumor behavior and biological activity. Because many cancers release small numbers of tumor cells into the bloodstream, analyzing these cells can provide real-time insights into tumor biology without invasive procedures.
What RGCC Testing Evaluates
RGCC testing may analyze several biological components related to tumor activity.
Circulating Tumor Cells (CTCs)
Circulating tumor cells are cancer cells that have entered the bloodstream from a primary tumor. . Measuring these cells may help clinicians understand disease activity or biological progression over time.
Genetic and Molecular Markers
Certain molecular markers associated with tumor behavior, treatment response, or metastatic potential may be evaluated.
Drug Sensitivity Patterns
Some RGCC panels assess how cancer cells respond in a controlled laboratory environment to various agents, including:
- Chemotherapy drugs
- Targeted therapies
- Selected repurposed medications
These results provide functional laboratory data that may contribute to clinical discussions.
Immune-Related Markers
Testing may also evaluate markers associated with immune activity, which may be relevant in integrative or immunologically oriented oncology strategies.
How This Differs from a Standard Biopsy
Traditional cancer diagnostics typically rely on tissue biopsies and imaging studies.
RGCC testing uses a liquid biopsy approach, analyzing tumor-related cells and markers circulating in the bloodstream.
This approach may offer several potential advantages:
- Less invasive sample collection
- A snapshot of circulating tumor biology in real time
- The ability to monitor biological changes over time
However, liquid biopsy testing is generally considered complementary to, not a replacement for, conventional oncology diagnostics.
Who Uses This Type of Testing?
RGCC testing is most commonly utilized by clinicians working within integrative oncology and functional oncology frameworks.
- Integrative oncology physicians
- Functional medicine oncology practitioners
- Physicians exploring personalized cancer therapy approaches
The goal is often to gain additional biological insight that may help guide collaborative decision-making with a patient’s oncology team.
How Testing May Inform a Personalized Strategy
Results from RGCC testing may contribute to discussions about personalized cancer care by helping clinicians:
- Identify potential molecular targets associated with tumor activity
- Evaluate adjunctive or investigational therapeutic considerations
- Monitor circulating tumor cell levels over time
- Understand how cancer cells behave in laboratory testing environments
For some patients, these insights may also inform discussions around precision-designed molecular therapies such as SOT therapy or QEstrain therapy, which are based on an individual tumor profile.
These therapies are considered investigational and adjunctive and should always be discussed within the context of a patient’s broader oncology care plan.
Important Considerations
Functional testing evaluates how cancer cells behave outside the body in a laboratory environment.
While this can provide valuable biological insight, it is important to understand the limitations:
- Laboratory responses do not guarantee clinical outcomes
- Results should be interpreted cautiously and in collaboration with a treating oncologist
- Testing is not universally considered the standard of care for treatment selection
At IHAWMD, we emphasize:
- Evidence-aware interpretation
- Collaborative oncology communication
- Clear expectations and transparency
Our role is to help patients understand the data, not replace their oncology team’s medical guidance.
Order RGCC Testing Through IHAWMD
If you are exploring additional options alongside your current cancer care, RGCC molecular testing may provide useful biological insight.
At Internal Healing and Wellness MD, we help patients:
- Determine whether testing may be appropriate
- Coordinate sample collection and laboratory processing
- Review results in a clear and responsible way
- Integrate findings into collaborative oncology discussions
Frequently Asked Questions
A circulating tumor cell test analyzes cancer cells that may be present in the bloodstream. These cells can provide information about tumor biology and disease activity.
No. These tests provide laboratory data only and do not guarantee treatment outcomes.
Yes. RGCC testing is considered a type of liquid biopsy cancer test, because it analyzes blood samples rather than requiring surgical tissue extraction.
No. Molecular therapies are considered investigational or adjunctive approaches and should always be discussed with a qualified oncology team.
Patients exploring integrative oncology, functional oncology, or personalized cancer therapy approaches sometimes seek additional biological insights through molecular testing.
Explore RGCC Testing With Our Team Today
If you would like to learn more about circulating tumor cell testing, molecular cancer analysis, or RGCC laboratory testing, we invite you to schedule a consultation with our team.
Our goal is to help you understand your options, interpret complex data responsibly, and make informed decisions within your oncology care plan.